ecallantide and Arthritis--Rheumatoid

To ascertain the participation of the plasma kallikrein-kinin system (KKS) in arthritis and inflammatory bowel disease, we used two rat models resembling rheumatoid arthritis and Crohn's disease. Proteoglycan-polysaccharide from group A streptococcus (PG-APS) produced chronic destructive inflammation and systemic response in the genetically susceptible Lewis rat, in the joints when injected intraperitoneally and in the bowel when injected into the gut wall. In both models, the KKS is activated, as evidenced by decreased prekallikrein, factor XI and high molecular weight kininogen. A specific plasma kallikrein inhibitor, Bz-Pro-Phe-boroarginine, reverses the plasma changes as well as the clinical gross and microscopic pathology of both the experimental arthritis and the inflammatory bowel disease in the genetically susceptible rats. We have also shown that the tissue kallikrein system is involved in the intestinal inflammatory changes. Intestinal tissue kalikrein (ITK) is localized in goblet cells in both normal and inflamed tissue. In chronic granulomatous inflammation, ITK is localized in macrophages. ITK decreases in chronic inflammation, probably due to secretion, since the mRNA is unchanged. Kallikrein binding protein, the ITK inhibitor, decreases due to enzyme-inhibitor complexes. Both plasma and tissue kallikrein are appealing targets for drug therapy of rheumatoid arthritis and Crohn's disease.

Topics: Animals; Arthritis, Rheumatoid; Disease Models, Animal; Humans; Inflammatory Bowel Diseases; Intestines; Plasma Kallikrein; Polysaccharides, Bacterial; Proteoglycans; Rats; Rats, Inbred Lew; Tissue Kallikreins

Dysregulated complement activation, increased protein citrullination, and production of autoantibodies against citrullinated proteins are hallmarks of rheumatoid arthritis (RA). Citrullination is induced by immune cell-derived peptidyl-Arg deiminases (PADs), which are overactivated in the inflamed synovium. We characterized the effect of PAD2- and PAD4-induced citrullination on the ability of the plasma-derived serpin C1-inhibitor (C1-INH) to inhibit complement and contact system activation.. Citrullination of the C1-INH was confirmed by ELISA and Western blotting using a biotinylated phenylglyoxal probe. C1-INH-mediated inhibition of complement activation was analyzed by C1-esterase activity assay. Downstream inhibition of complement was studied by C4b deposition on heat-aggregated IgGs by ELISA, using pooled normal human serum as a complement source. Inhibition of the contact system was investigated by chromogenic activity assays for factor XIIa, plasma kallikrein, and factor XIa. In addition, autoantibody reactivity to native and citrullinated C1-INH was measured by ELISA in 101 RA patient samples.. C1-INH was efficiently citrullinated by PAD2 and PAD4. Citrullinated C1-INH was not able to bind the serine protease C1s and inhibit its activity. Citrullination of the C1-INH abrogated its ability to dissociate the C1-complex and thus inhibit complement activation. Consequently, citrullinated C1-INH had a decreased capacity to inhibit C4b deposition. Citrullination of the C1-INH by recombinant human PAD2 and PAD4 enzymes impaired its ability to inhibit the complement and contact systems

Topics: Arthritis, Rheumatoid; Autoantibodies; Citrullination; Factor XIa; Factor XIIa; Humans; Plasma Kallikrein; Protein-Arginine Deiminases; Proteins

We evaluated the activities of salivary kallikrein and tissue/plasma kallikreins, and the plasma levels of high-molecular (HKg) and low-molecular (LKg) weight kininogens in patients with rheumatoid arthritis. The patients exhibited higher levels of the active salivary kallikrein compared to the controls. In contrast, the total salivary kallikrein activity of patients was not different from controls. In plasma from the patients, tissue kallikrein activity or plasma prekallikrein activity was not significantly different from the controls. Plasma HKg levels observed in patients were higher than in controls, whereas plasma LKg levels did not differ significantly from controls. Our results showed that most of the salivary kallikrein seen in patients is in its active form, suggesting the presence of systemic or local factors with the ability to activate salivary pro-kallikrein.

Topics: Arthritis, Rheumatoid; Female; Humans; Kininogens; Middle Aged; Plasma Kallikrein; Saliva; Tissue Kallikreins